Keeping Track: A Burst of CRLs and BTDs, A Busy Week Of Submissions And Another Approval For Soliris
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Apadaz Approved Without Abuse-Deterrent Label, FDA Denies Translarna Appeal, And Some Priority Reviews
The latest drug development news and highlights from our US FDA Performance Tracker.
CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018
Rare disease and infectious disease candidates also are among the most common treatments in agency's review queue.